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The Korean Society for Cytopathology (KSC) has conducted 
the Continuous Quality Improvement program for cytopathology 
laboratories in Korea since 1995 [1]. In 1992, the Committee 
of Quality Improvement of the KSC (CQIKSC) was first founded. 
In 1995, the standard operating procedures and documents of 
quality assurance (QA) were enacted, and the first nationwide 
survey of annual statistics on cytologic exams of all institutions 
was conducted. In 1996, the first proficiency tests (PTs) and the 
certification of participating institutions were performed with 
100 institutions. Since 2003, all cytopathology laboratories in 
Korea have been obliged to submit annual statistics and partici-
pate in PTs to be certified by the CQIKSC. The number of par-
ticipating institutions was 148 in 2004 and increased to 211 in 
2018. Currently, the certification awarded through the Contin-
uous Quality Improvement program is regarded as an impor-
tant standard to qualify individual cytopathology laboratories, 
especially in conjunction with the National Cancer Screening 
Program that was started in 1999 [1-3].
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Background: The Korean Society for Cytopathology has conducted the Continuous Quality Improvement program for cytopathology 
laboratories in Korea since 1995. In 2018 as part of the program, an annual survey of cytologic data was administered to determine the 
current status of cytopathology practices in Korea. Methods: A questionnaire was administered to 211 cytopathology laboratories. Indi-
vidual laboratories submitted their annual statistics regarding cytopathology practices, diagnoses of gynecologic samples, inadequacy 
rates, and gynecologic cytology-histology correlation review (CHCR) data for 2018. In addition, proficiency tests and sample adequacy 
assessments were conducted using five consequent gynecologic slides. Results: Over 10 million cytologic exams were performed in 
2018, and this number has almost tripled since this survey was first conducted in 2004 (compounded annual growth rate of 7.2%). The 
number of non-gynecologic samples has increased gradually over time and comprised 24% of all exams. The overall unsatisfactory rate 
was 0.14%. The ratio of the cases with atypical squamous cells to squamous intraepithelial lesions accounted for up to 4.24. The major 
discrepancy rate of the CHCR in gynecologic samples was 0.52%. In the proficiency test, the major discrepancy rate was approximately 
1%. In the sample adequacy assessment, a discrepancy was observed in 0.1% of cases. Conclusions: This study represents the current 
status of cytopathology practices in Korea, illustrating the importance of the Continuous Quality Improvement program for increasing 
the accuracy and credibility of cytopathologic exams as well as developing national cancer exam guidelines and government projects 
on the prevention and treatment of cancer.
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The Continuous Quality Improvement program initially con-
sisted of an annual survey of the statistics on gynecological (GYN) 
cytologic exams. Recently, the survey has been expanded to cover 
overall statistics, statistics on the diagnostic category of GYN 
exams, inadequacy rates, cytology-histology correlation reviews 
(CHCRs), and the number of discordant cases. PTs were initially 
performed 2–4 times annually using three slides; however, in 
2013, this was adjusted to once annually using five glass slides. 
Sample adequacy evaluations have been performed with five 
GYN slides submitted from participating institutions since 2013. 
Since 2009, six glass slides from each participating institution 
have been submitted to be used in the PTs for the following years. 
The statistical analysis of the submitted data has been unoffi-
cially performed by CQIKSC to efficiently develop a strategy for 
quality improvement. Official reports have only been published 
twice: in 2008 (using data collected before 2007) [1] and 2017 
(using data collected before 2016) [4]. A new report using the 
data collected between 2007 and 2017 is currently being com-
piled for publication. The Continuous Quality Improvement 
statistics are very credible and represent the current status of 
cytopathology practices in Korea [4]. In addition, quality data to 
support the creation of national policies and strategies in cancer 
screening are becoming more essential [5]; therefore, CQIKSC 
has decided to publish the statistics annually. 
Thus, we present the results of a nationwide survey on annual 
statistics from cytologic exams and PTs for 2018. 
MATERIALS AND METHODS
The Continuous Quality Improvement program by CQIKSC
As mentioned earlier, the annual Continuous Quality Im-
provement program consists of four parts: 1, a survey of the sta-
tistics on the cytologic exams performed in the last year; 2, a 
PT using five glass slides; 3, a sample adequacy evaluation of five 
GYN glass slides submitted by the participating institutions; 
and 4, submission of six candidate slides by the participating 
institutions to be used in the PTs of the following years. 
Annual survey of cytopathology statistics
A nationwide survey was conducted by CQIKSC from February 
11, 2019, to February 22, 2019. The questionnaire and the writ-
ten informed consent were collected from 211 medical institu-
tions performing cytopathologic examinations in Korea in 2018. 
The questionnaire included the statistical data on overall cyto-
logic exams, the case number of the GYN exams according to the 
diagnostic categories, the GYN sample adequacy, the CHCR 
results, and the number of discordant cases according to the 
discordant assessment criteria. The diagnostic concordance be-
tween the cytologic and corresponding histologic examination 
of the uterine cervix or endometrium was categorized as either 
concordant (category O) or one of three discordant categories: 
category A (minimal clinical impact), category B (minor clinical 
impact), or category C (major clinical impact). The criteria for 
CHCR were developed by the individual institutes according 
to the internal guidelines for laboratory QA. The discordant as-
sessment criteria for PT by CQIKSC were provided to each insti-
tute as a reference for the criteria for CHCR (Tables 1–4). 
The participating institutions were categorized into three 
groups: university hospitals, general hospitals, and commercial 
laboratories. The overall cytologic exam statistics were analyzed 
by category. The sample categories were as follows: GYN, fine-
needle aspiration (FNA), and non-GYN/non-FNA sample ex-
ams including urine, body fluids, respiratory tract samples (spu-
tum, bronchial washing, brushing, bronchioloalveolar lavage, 
etc.), cerebrospinal fluid, etc. Endoscopic bronchial ultrasonog-
raphy-assisted aspiration cytology samples were classified as 
FNA samples other than body fluids. The cystic fluids derived 
from anatomical body cavities, such as the pleural, peritoneal, 
or pericardial cavities, were classified as body fluids although they 
were obtained by needle aspiration. 
Table 1. Discordance assessment criteria for gynecologic samples, squamous lesions
Original diagnosis
Submitted diagnosis
Negative ASC-US ASC-H L-SIL H-SIL Carcinoma
Negative O A B A B C
ASC-US A O A O A B
ASC-H B A O A O B
L-SIL A A A O A B
H-SIL B B A A O A
Carcinoma C B B B A O
ASC-US, atypical squamous cells of undetermined significance; ASC-H, atypical squamous cells, cannot exclude H-SIL; L-SIL, low-grade squamous intraepi-
thelial lesion; H-SIL, high-grade squamous intraepithelial lesion.
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Proficiency test
The second part of the Continuous Quality Improvement 
program, the PT, was performed in 209 medical institutions 
from May 3, 2019, to May 25, 2019, using a total of 1,045 glass 
slides. Five glass slides (2 GYN slides, 1 body fluid or urine, 2 
respiratory tract sample or FNA slides) were dispatched to the 
participating institutions by parcel post. The candidate cases for 
PT, along with their cytologic diagnoses and the corresponding 
histologic diagnoses, were collected from the participating insti-
tutions in 2015 and 2016. The cases were reviewed by mem-
bers of the CQIKSC and their eligibility for PT was confirmed. 
The diagnosis submitted by participating institutions was based 
Table 2. Discordance assessment criteria for gynecologic samples, glandular lesions
Original diagnosis
Submitted diagnosis
Negative AGC AGC, favor neoplastic Endocervical AIS Adenocarcinoma
Negative O A B B C
AGC A O A B B
AGC, favor neoplastic B A O A A
Endocervical AIS B B A O A
Adenocarcinoma C B A A O
AGC, atypical glandular cells; AIS, adenocarcinoma in situ.





































Benign, c/w a benign 
follicular nodule
O A A B B C C C C
Benign, c/w chronic 
lymphocytic (Hashimoto’s) 
thyroiditis
A O A B B C C C C
Benign, c/w granulomatous 
(subacute) thyroiditis
A A O B B C C C C
Benign, other A A A B B C C C C
AUS or FLUS A A A A A B B B B
Follicular lesion, 
conventional type
B B B O A A B B B
Follicular lesion, Hurthle cell 
(oncocytic type)
B B B B O A B B B
Suspicious for papillary 
carcinoma
C C C B B O B B B
Suspicious for poorly 
differentiated carcinoma
C C C B B B O B B
Suspicious for medullary 
carcinoma
C C C B B B B O B
Suspicious for 
undifferentiated carcinoma
C C C B B B B B O
Suspicious for lymphoma C C C B B B B B B
Suspicious for malignancy, 
other
C C C B B A B B B
Papillary carcinoma C C C A A O A A A
Poorly differentiated 
carcinoma
C C C B B A O A A
Medullary carcinoma C C C B B A A O A
Undifferentiated (anaplastic) 
carcinoma
C C C B B A A A O
Malignant, other C C C B B A A A A
c/w, consistent with; AUS, atypia of undetermined significance; FLUS, follicular lesion of undetermined significance.
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on the Bethesda system [6] for GYN samples and on the thyroid 
Bethesda system [7] for thyroid FNA samples. The submitted 
diagnoses were evaluated using the discordance assessment cri-
teria (Tables 1–4), and the diagnostic concordance was catego-
rized as either concordant (category O) or as one of three discor-
dant categories: category A (minimal clinical impact), category 
B (minor clinical impact), or category C (major clinical impact). 
The criteria for PT have been developed and modified by CQ-
IKSC based on the potential clinical impact in relation to the 
clinical treatment guidelines.
Sample adequacy assessment
The third part of the program was the sample adequacy as-
sessment. Each participating institution was asked to submit 
five GYN glass slides of any consequent number and the corre-
sponding reported adequacy that were diagnosed in each insti-
tution on March 5, 2018. They were submitted to the CQIKSC 
from September 10, 2018, to September 21, 2018, and the sam-
ple adequacy was reevaluated by the members of the CQIKSC. 
Submission of samples for the QA program
For the final part of the program, each participating institu-
tion was asked to submit six glass slides (2 GYN, 2 non-GYN, 
and 2 FNA) with confirmed cytologic diagnoses and the corre-
sponding histologic diagnoses from November 26, 2018, to 
December 7, 2018. The eligibility of the collected samples for 
the PT was evaluated by the members of the CQIKSC, and eli-
gible samples were archived to be used in the PT in the following 
years. 
Statistical analysis
The correlation between total case numbers, liquid-based 
preparation (LBP) coverage, atypical squamous cells to squa-
mous intraepithelial lesions ratio (ASC/SIL ratio) of participant 
institutions in 2018 was done using Pearson correlation analysis 




Responses were obtained from all 211 medical institutions, 
including 83 university hospitals (39.3%), 84 general hospitals 
(39.8%), and 44 commercial laboratories (20.8%) (Fig. 1). The 
number of participating institutions steadily increased from 
148 in 2004 to 211 in 2018. In particular, the number of com-
mercial laboratories significantly increased from 25 (14.6%) in 
2009 to 44 (20.8%) in 2018, while the number of general and 
university hospital laboratories slightly increased.
Overall statistics
The total number of cytopathologic examinations performed 
in 2018 was 10,057,839; this number was more than triple the 
number of examinations performed in 2004 (2,891,867, com-
pounded annual growth rate: 7.2%) (Fig. 1). The number of 
cytologic exams performed was 1,695,625 in university hospitals 
(16.9%), 732,880 in general hospitals (7.3%), and 7,629,334 
in commercial laboratories (75.9%). In 2018, commercial labo-
ratories only comprised approximately 20% of the total institu-
tions but performed over 75% of the total examinations (Supple-
mentary Fig. S1). In 2015, commercial laboratories comprised 
17.5% of the participating institutions (36 out of 206) and per-
formed 5,717,336 out of 8,284,952 exams (69.0%), illustrating 
a significant increase of the segment share (69.0% to 75.9%) 
and the number of institutions (17.5% to 20.8%). In 2018, the 
average number of cytologic exams was 20,429 in university 
hospitals, 8,724 in general hospitals, and 173,393 in commer-
cial laboratories. In 2015, the average number of cytologic exams 
was 19,320 in university hospitals, 11,080 in general hospitals, 
and 158,814 in commercial laboratories, illustrating a significant 
increase in the number of exams in university hospitals and com-
mercial laboratories and a significant decrease in the number of 
exams in general hospitals.
GYN and non-GYN samples
In 2018, the total number of GYN samples was 7,641,281 
(76.0%), and the total number of non-GYN samples was 
Table 4. Discordance assessment criteria for body fluid, urine, and other fine-needle aspiration samples
Original diagnosis
Submitted diagnosis
Negative or benign Atypical, favor reactive Atypical, favor neoplastic Malignant Malignant, but different diagnosis
Benign O A B C C
Atypical, favor reactive A O A B B
Atypical, favor neoplastic B A O A A
Malignant C B A O A
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2,416,558 (24.0%). The percentage of non-GYN samples 
gradually increased from 14% in 2007 to 24.0% in 2018. The 
majority (approximately 80.9%) of the GYN samples were ana-
lyzed in commercial laboratories (n = 6,181,796), while only 
6.7% and 12.5% were processed by general and university hospi-
tals, respectively. The proportion of GYN samples analyzed by 
commercial laboratories significantly increased from 58.0% in 
2004 and 74.2% in 2015 to 80.9% in 2018; however, from 2015 
to 2018, this number was similar in university hospitals (13.8% 
and 12.5%) and significantly decreased in general hospitals 
(11.1% to 6.7%). The proportion of non-GYN samples was 
highest in university hospitals (44%), followed by general hos-
pitals (31%) and commercial laboratories (19%). 
The primary types of non-GYN samples were body fluids (n = 
1,664,313, 68.9%), followed by urine (n = 431,749, 17.9%) 
and FNA (n = 320,496, 13.3%). The majority of the body fluids 
were obtained from the respiratory system (e.g., sputum, bron-
chial washing, or bronchial brushing, n = 1,508,676, 90.6%) (Fig. 
2A). Most of the FNA samples were taken from the thyroid (n = 
225,511, 70.4%). The FNA and urine samples were more com-
mon in the university (17.4% and 30.6%, respectively) and gen-
eral hospitals (18.9% and 24.2%, respectively), while body fluids 
from the respiratory tract comprised the majority of the commer-
cial laboratory samples (79.4%) (Fig. 2B).
Conventional and LBP cytology
Of all the samples, 8,030,418 (79.8%) samples were prepared 
by conventional smear, and 2,027,421 (20.2%) samples were 
prepared by LBP. The LBP method was used in 19.5% of the 
GYN (n = 1,493,582) and 22.1% of the non-GYN samples (n = 
533,839), including 44.4% of the urine (n = 191,769), 43.6% 
of the FNA (n = 139,599), and 12.1% of the body fluid (n = 
202,471) samples (Fig. 3A). The LBP coverage of the GYN 
samples slightly decreased from 2017 to 2018 (20.3% to 19.5%). 
The LBP coverage of the non-GYN samples also decreased 
from 2017 to 2018 (25.2% to 22.1%), although the coverage 
was significantly increased in the FNA and urine subsets among 
the non-GYN samples. This indirectly suggests that from 2017 
to 2018 a relatively high increase of GYN and body fluid sam-
ples were prepared by conventional methods (Fig. 3A). The LBP 
coverage of the GYN samples increased from 2017 to 2018 in 
both university and general hospitals, while it decreased in 
commercial laboratories (Fig. 3B). This pattern was similar in the 
non-GYN samples; the LBP coverage decreased only in commer-
cial laboratories in 2018 (Fig. 3C). Among the subsets of the 
non-GYN samples, the LBP coverage generally increased in the 
FNA and urine samples of all institutions, while it only decreased 
in the body fluid samples of the commercial laboratories. (Fig. 
3D–F). Chronologically, the LBP coverage in the GYN samples 
increased from 7.6% in 2004, reached a peak of 29.0% in 2012, 
and decreased slightly to 19.5% in 2018 (Fig. 3G). 
Distribution of the GYN sample cytologic diagnoses 
The cytologic diagnoses percentages of the GYN samples are 
summarized in Table 5. The percentage of the samples with 
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Fig. 1. Overall statistics of cytopathology exams from 2004 to 2018. GYN, gynecologic samples; Non-GYN, non-gynecologic samples.
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centage of the “negative” samples was 95.29%. The percentage 
of “atypical squamous cells of undetermined significance” 
(ASC-US) and “atypical squamous cells-cannot exclude high-
grade squamous intraepithelial lesion” were 3.45% and 0.19%, 
respectively. The percentage of “low-grade squamous intraepi-
thelial lesion” and “high-grade squamous intraepithelial lesion” 
were 0.65% and 0.19%, respectively. The ratio of ASC-US to 
squamous intraepithelial lesion (SIL) was 4.25 in 2018. Compared 
to 2017, the percentage of ASC-US increased from 3.47% to 
3.69%, and the percentage of SIL decreased from 0.91% to 
0.87%. 
Although the total number of GYN samples increased sig-
nificantly from 5,640,080 in 2012 to 7,706,455 in 2018 as the 
coverage of the National Cancer Screening Program increased, the 
total number of SIL and cancer slightly decreased from 71,722 in 
2012 to 67,063 in 2018 and 2,847 in 2012 to 2,042 in 2018, re-
spectively (Fig. 4A). In contrast, the atypical squamous cell (ASC) 
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Fig. 2. Number and proportion of cytopathology exams according to types of sample (A) and institution (B). GYN, gynecologic samples; 
Non-GYN, non-gynecologic samples; FNA, fine-needle aspiration; CSF, cerebrospinal fluid; ERCP, endoscopic retrograde cholangiopancrea-
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Fig. 3. Proportion of conventional smear (CS) and liquid-based preparation (LBP) cytology. Change in proportion between 2017 and 2018 of 
all samples (A), gynecologic samples (GYN) (B), non-gynecologic samples (Non-GYN) (C), fine-needle aspiration (FNA) (D), urine (E), and 
body fluid (F). (G) Proportion of CS and LBP cytology of gynecologic samples from 2004 to 2018. Univ. Hos., university hospitals; Gen. Hos., 












2018. As a result, the ASC/SIL ratio increased from 2.98 in 2012 
to 4.24 in 2018. With regard to institutions, the ASC/SIL ratio 
was steadily maintained at approximately 1.8 in university hos-
pitals and 2.5 in general hospitals; however, it has continuously 
increased in commercial laboratories from 3.68 in 2012 to 5.65 
in 2018 (Fig. 4B). A correlation analysis using the data from all 
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211 institutions showed that the laboratories with more cases 
tended to use less LBP and report a higher ASC/SIL ratio, although 
these findings were not statistically significant (Fig. 4C, D). 
Moreover, the laboratories that used more LBP tended to report 
significantly lower ASC/SIL ratios (Fig. 4E). 
CHCR for the GYN cytology
As part of the internal quality control (QC) program, each 
institution was asked to compare the diagnoses of the cytologic 
and histologic samples of the same individual whenever possible 
and to document the degree of discordance between the cytologic 
and histologic diagnoses according to the institutional criteria. Of 
69,808 cases, 60,823 cases showed concordant results between 
the cytologic and histologic diagnoses (87.1%) (Fig. 5A). Dis-
cordance with minimal and minor clinical impact (categories A 
and B) were found in 6,555 and 2,301 cases, respectively (9.4% 
and 3.3%) (Fig. 5B). Discordance with major clinical impact 
(category C) was found in 361 cases (0.52%) (Fig. 5B). Over 
the past 15 years, while an increasing number of cases have been 
compared, the discordant rate has been steadily maintained at 
approximately 15% (Fig. 5A). However, the rates of discor-
dance with minor and major clinical impact (categories B and 
C) have markedly decreased from 4.40% and 1.5% in 2003 to 
3.30% and 0.52% in 2018, respectively (Fig. 5B).
Adequacy of GYN samples
The percentage of the GYN samples with unsatisfactory ade-
quacy in each institution was collected as a part of the annual sur-
vey. The overall unsatisfactory rate was 0.14% in 2018 and 
0.24% in 2017. It was 0.45% in university hospitals, 0.44% in 
general hospitals, and 0.07% in commercial laboratories in 2018. 
Proficiency test
The PT using 1,045 dispatched glass slides showed 84.6% 
overall concordance (category O), 12.2% discordance with 
minimal clinical impact (category A), 2.2% discordance with 
minor clinical impact (category B), and 0.95% discordance with 
major clinical impact (category C) (Fig. 6A). The concordance 
rates reported by the institutions were 86.6% in university hos-
pitals, 85.9% in general hospitals, and 78.1% in commercial 
laboratories; discordance with major clinical impact (category 
C) was 1.0% in university hospitals, 1.2% in general hospitals, 
and 0.5% in commercial laboratories (Fig. 6A). Of the 420 
GYN cytology cases, the overall concordance rate was 75.2%, 
minimal discordance (category A) was 21.0%, minor discor-
dance (category B) was 2.8%, and major discordance (category 
C) was 0.5% (Fig. 6B). Concordance reported by the institu-
tions was 77.4%, 77.6%, and 67.9% in university hospitals, 
general hospitals, and commercial laboratories, respectively. 
Major discordance (category C) was 0.6%, 0.6%, and 0.0% in 
the university hospitals, general hospitals, and commercial lab-
oratories, respectively (Fig. 6B). Of the 164 thyroid FNA cases, 
the overall concordance was 95.7%, and the major discordance 
was 1.2% (Fig. 6C). The concordance rates by institution were 
similar in the university hospitals (98.5%), general hospitals 
(95.4%), and commercial laboratories (90.9%). Major discor-
dance was found in only two cases (3.1%) in the general hospi-
tals (Fig. 6C). Of the 300 body fluid cases, the overall concor-
dance was 91.0% and the major discordance rate was 1.0% 
(Fig. 6D). The concordance rate was 92.4%, 92.6%, and 85.0% 
in the university hospitals, general hospitals, and commercial 
laboratories, respectively. Major discordance was found in one 
case in each institution (0.8%, 0.8%, and 1.7% in university 
hospitals, general hospitals, and commercial laboratories, re-
spectively) (Fig. 6D). Of the 108 urine cytology cases, the overall 
concordance rate was 85.2%, and the major discordance rate was 
1.9% (Fig. 6E). The concordance rate was 86.0%, 89.1%, and 
73.7% in the university hospitals, general hospitals, and com-
mercial laboratories, respectively. Major discordance was found 
in one case in the general hospitals and in the commercial labo-
ratories (2.2% and 5.3%, respectively) (Fig. 6E). Among 55 other 
FNA cases, the overall concordance rate was 83.6%, and the 
major discordance rate was 5.5% (Fig. 6F). The concordance rate 
was 88.9%, 78.3%, and 85.7% in the university hospitals, gen-
eral hospitals, and commercial laboratories, respectively. Major 
Table 5. Distribution of the gynecologic sample cytologic diagnoses
Cytologic diagnosis 2017 2018
Unsatisfactory 0.24 0.14







AGC, favor neoplastic 0.01 0.01
L-SIL 0.70 0.65
H-SIL 0.20 0.19
Squamous cell carcinoma 0.02 0.02
Adenocarcinoma 0.00 0.01
ASC/SIL ratio 3.82 4.25
ASC, atypical squamous cells; ASC-US, atypical squamous cells of uncer-
tain significance; ASC-H, atypical squamous cells, cannot exclude H-SIL; 
AGC, atypical glandular cells; L-SIL, low-grade squamous intraepithelial le-
sion; H-SIL, high-grade squamous intraepithelial lesion; ASC/SIL ratio, 
atypical squamous cells/squamous intraepithelial lesion ratio.
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Fig. 4. Trends in gynecologic sample cytologic diagnoses from 2012 to 2018 and correlation analysis according to atypical squamous cells 
to squamous intraepithelial lesions ratio (ASC/SIL ratio). Trends in the number of total gynecologic (GYN) samples, atypical squamous cells 
(ASC), squamous intraepithelial lesions (SIL), cervical cancers, and ASC/SIL ratio from 2012 to 2018 (A), ASC/SIL ratio according to institu-
tions (B), correlation of total case number versus liquid-based preparation (LBP) coverage among 211 participating institutions in 2018 (C), 
correlation of total case number versus ASC/SIL ratio in 2018 (D), correlation of LBP coverage versus ASC/SIL ratio in 2018 (E). Com. Lab., 
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Fig. 5. The results of cytology-histology correlation review (CHCR) from 2003 to 2018. (A) Total number of CHCR cases and trends of the 
proportions of concordant (category O) and discordant cases. (B) Trends in discordant cases with minimal (category A), minor (category B), 
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Fig. 6. Proficiency test (PT) results according to institutions in 2018. Overall concordance of PT (A), and concordance of PT in gynecologic 
samples (B), thyroid fine-needle aspiration (FNA) cytology samples (C), body fluid samples (D), urine (E), and other FNA samples (F). GYN, 
gynecologic samples; Univ. Hos., university hospitals; Gen. Hos., general hospitals; Com. Lab., commercial laboratories.
discordance was found in two cases and one case in the university 
and general hospitals, respectively (11.1% and 4.3%, respectively) 
(Fig. 6F).
Sample adequacy assessment
A total of 193 participating institutions submitted a total of 
965 GYN slides of consequent numbers (5 slides from each in-
stitution) and their reported adequacy. The sample adequacy as-
sessments reevaluated by the members of the CQIKSC and the 
reported adequacy of the institutions in all cases were concordant.
Submission of samples for the next QA program
A total of 182 participating institutions submitted 961 glass 
slides with confirmed cytologic diagnoses and corresponding 
histologic diagnoses. 
DISCUSSION
The key findings of this study are summarized as follows: 1) the 
total number of cytopathologic exams is continuously increasing, 
and the proportion of non-GYN samples is gradually increasing 
over time; 2) the number of cytopathologic exams processed by 
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creasing in all samples except GYN and body fluid samples pro-
cessed by commercial laboratories; 4) the total number of GYN 
exams is increasing, but the number of cancer cases is decreas-
ing; 5) the ASC/SIL ratio is increasing (the ASC percentage is 
increasing while the SIL percentage is decreasing); 6) the high 
LBP coverage seems to be lowering the ASC/SIL ratio; 7) the 
major discordance rate found by the CHCR (internal QC as-
sessment) is decreasing over time; 8) the unsatisfactory rate in 
GYN samples is well under control; 9) the average diagnosis 
concordance rate of the PT (external QC assessment) is approxi-
mately 85% with a major discordance (category C) rate of less 
than 1%; and 10) the concordance rate was highest in thyroid 
FNA, lower in urine and other FNA, and lowest in GYN cytology.
The total number of cytopathologic exams has increased dra-
matically to over 10 million exams per year. It has more than 
tripled from the number of total exams in 2004 with a steady 
compounded annual growth rate of 7.2%. Furthermore, the 
growth has not slowed but rather reached a peak. In 2018, an 
annual average of 47,667 cases was processed by individual lab-
oratories that processed only 19,000 cases in 2004. This seems 
to be primarily due to the introduction of screening cytologic 
exams in the National Cancer Screening Program [1,2,8]. The 
proportion of non-GYN samples has also been gradually increas-
ing over time. This is probably because of an overall increase in 
cytologic exams (the subgroup proportions were not significantly 
different from the numbers in 2015).
The number of cytopathologic exams processed by commercial 
laboratories has been increasing. The average number of cyto-
logic exams reported by the institutions showed a bipolar distri-
bution; they significantly increased in university hospitals (19,320 
in 2015 to 20,429 in 2018) and commercial laboratories (158,814 
in 2015 to 173,393 in 2018) but decreased in general hospitals 
(11,080 in 2015 to 8,724 in 2018). This finding suggests that 
university hospitals and commercial laboratories have a need for 
more manpower. 
LBP coverage has generally increased in all samples, especially 
thyroid FNA and urine samples based on the wide acceptance 
of the technology in these samples [9]. However, it decreased in 
the GYN and body fluid samples processed by the commercial 
laboratories. This seems to be primarily due to the increase in 
National Cancer Screening Program samples where LBP meth-
ods are not covered by insurance. Because the total number of 
cytologic exams is significantly increasing and cytopathology man-
power is limited, expanding LBP coverage in the cancer screen-
ing program would be an effective strategy to manage increasing 
labor demands. 
Over the past few years, the total number of GYN exams has 
been increasing and the number of cancer cases has been de-
creasing. At the same time, the ASC/SIL ratio, an important QC 
parameter for GYN cytology exams [10], has been increasing 
(the ASC rate has been increasing while the SIL rate has been 
decreasing). This finding seems to be due to the expansion of the 
recipient age group of the National Cancer Screening Program. 
Since 2016, the National Cancer Screening Program has covered 
women over the age of 20 (previously, only women over the age of 
30 were covered), and the number of negative or ASC cases has 
increased while the number of SIL or cancer cases proportionally 
decreased [8]. The ASC/SIL ratio was more significantly increased 
in commercial laboratories than in the other institutions (3.68 in 
2012 to 5.65 in 2018), which explains the impact of the changes 
in the National Cancer Screening Program samples. Interestingly, 
in correlation analyses, the institutions with more samples tended 
to have less LBP coverage and to report higher ASC/SIL ratios, and 
high LBP coverage tended to significantly correlate with lower 
ASC/SIL ratios. As the registered cytotechnologists that per-
form cytology screening were estimated as 386 in 2017, the aver-
age number of GYN samples screened by a cytotechnologist is 
19,796.1 cases per year, approximately 79.2 cases per working 
day, which indicates that cytology laboratories in Korea have a 
labor-intensive working environment.
The major discordance (category C) rate in the CHCR of the 
GYN samples has been significantly decreasing over time to a level 
as low as 0.52%, and the unsatisfactory rate of GYN samples has 
been well controlled over time (0.14% in 2018). These findings 
show that the Continuous Quality Improvement program of KSC 
has gradually contributed to the improvement of cytopathologic 
exam quality in cytopathology laboratories in Korea over time. 
In the PT, the average diagnosis concordance rate was approx-
imately 85%, and the major discordance (category C) rate was 
less than 1% (0.95%). The concordance rate was the highest in 
thyroid FNA (95.7%), followed by body fluids (91.0%), urine 
(85.2%), and other FNA (83.6%); it was the lowest in GYN 
cytology (75.2%). This finding seems to be due to the sample 
characteristics and the varying degrees of complexity of the di-
agnostic categories. In GYN cytology, the major discordance 
(category C) was less than 0.5%, while the minimal and minor 
discordance (categories A and B) composed almost one-fourth 
of the total samples (24.3%). This finding indirectly shows the 
complexity of the diagnostic category (Bethesda system [6]) of 
GYN cytology. In contrast, in thyroid FNA, the concordance rate 
was over 95%. This seems to stem from the monotonous com-
position of PT samples. The occurrence of the minor categories of 
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thyroid FNA, such as medullary carcinoma, poorly differentiated, 
or undifferentiated carcinoma was relatively rare, and these cat-
egories were not properly included in the PT sample pools. A 
more balanced sample composition for the PT should be carefully 
designed in the future. In comparison with the prior results of 
PT in 2004 and 2007, the concordant rate slightly but gradu-
ally increased from 73.0% in 2004 and 74.5% in 2007 to 75.2% 
in 2018 [1]. The major discordant rate (category C) also gradu-
ally decreased from 2.8% in 2004 and 2.0% in 2007 to 0.5% 
in 2018 [1]. However, because the discordance assessment cri-
teria for PT have been slightly modified by the CQIKSC during 
the period as clinical treatment guidelines have changed, it is rec-
ommended that this data should be interpreted with care.
For the fourth part of the program, each participating insti-
tution has submitted candidate slide samples for the next PT pro-
gram (182 institutions, 961 slides). However, there are several 
drawbacks to using these glass slides in the PT program. Not 
enough samples have been submitted every year. There is a possi-
bility of sample loss or damage during packaging, handling, and 
storage, which can lead to the leakage of personal information. 
The level of diagnostic difficulty of each PT sample is variable, 
and the PT samples may be distributed disproportionately. The 
PT samples can easily become discolored over time during stor-
age. Because of the aforementioned reasons, the introduction of 
a digital pathology system in the QC programs is being uti-
lized in other programs such as United Kingdom National 
External Quality Assessment Site (UKNEQAS) and The Royal 
College of Pathologists of Australasia Quality Assurance Programs 
(RCPAQAP) [11,12]. In 2019, CQIKSC will also attempt to 
adopt the digital pathology system for the Continuous Quality 
Improvement programs with the collaboration of the Committee 
of Quality Assurance of the Korean Society of Pathologists. The 
efficacy of the digital pathology system in the Continuous Quality 
Improvement program will be assessed during its establishment. 
With the results of this study, we confirmed that the Contin-
uous Quality Improvement programs using the annual survey and 
the internal (CHCR) and external QC tests (PT) in the KSC 
have contributed to improved cytopathology practice perfor-
mance quality by enhancing diagnostic accuracy. However, the 
high ASC/SIL ratio in a few institutions should be further mon-
itored as the National Cancer Screening Programs expand over 
time. Active intervention and QC surveillance of each institution 
must be continued.
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